var data={"title":"Magnesium citrate: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Magnesium citrate: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6495?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=magnesium-citrate-patient-drug-information\" class=\"drug drug_patient\">see &quot;Magnesium citrate: Patient drug information&quot;</a> and <a href=\"topic.htm?path=magnesium-citrate-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Magnesium citrate: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3884001\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Citroma [OTC];</li>\n      <li>GoodSense Magnesium Citrate [OTC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F190827\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Citro-Mag</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F190839\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Laxative, Saline;</li>\n      <li>\n        Magnesium Salt</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F190828\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Laxative:</b> Oral: Solution: 195-300 mL given once or in divided doses</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F190835\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=magnesium-citrate-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Magnesium citrate: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Laxative:</b> Oral: Solution:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Children 2-6 years: 60-90 mL given once or in divided doses (maximum: 90 mL/24 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Children 6-12 years: 90-210 mL given once or in divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Children &ge;12 years and Adolescents: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F190829\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F190830\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment provided in manufacturer&rsquo;s labeling; however, magnesium is renally excreted. Use caution; accumulation of magnesium in renal impairment may lead to magnesium toxicity.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F190812\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Citroma: 1.745 g/30 mL (296 mL) [contains polyethylene glycol, saccharin sodium; lemon flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Citroma: 1.745 g/30 mL (296 mL) [low sodium; lemon flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Citroma: 1.745 g/30 mL (296 mL) [low sodium; contains fd&amp;c red #40, saccharin sodium; cherry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">GoodSense Magnesium Citrate: 1.745 g/30 mL (296 mL) [contains polyethylene glycol, saccharin sodium]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">GoodSense Magnesium Citrate: 1.745 g/30 mL (296 mL) [low sodium; contains alcohol, usp, fd&amp;c red #40, saccharin sodium]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">GoodSense Magnesium Citrate: 1.745 g/30 mL (296 mL) [low sodium; contains saccharin sodium; lemon flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1.745 g/30 mL (296 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 100 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F190799\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21963502\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">1 g magnesium citrate &asymp; elemental magnesium 160 mg = magnesium 13 mEq = magnesium 6.5 mmol</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F190816\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">To increase palatability, chill the solution prior to administration. Administer each dose with 8 oz of water.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F190815\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Occasional constipation:</b> Treatment of occasional constipation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25730798\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Evacuation of bowel prior to certain surgical and diagnostic procedures or overdose situations</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F190806\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">Frequency not defined: Gastrointestinal: Abdominal pain, diarrhea, flatulence, nausea, vomiting</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25855567\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">OTC  labeling:  When used for self-medication, do not use if on low salt diet</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F190803\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Constipation (self-medication, OTC use): Appropriate use: For occasional use only; serious side effects may occur with prolonged use. For use only under the supervision of a physician in patients with kidney dysfunction, sodium- or magnesium-restricted diets, abdominal pain/nausea/vomiting, with a sudden change in bowel habits which has persisted for &gt;2 weeks, or use of a laxative for &gt;1 week. If rectal bleeding develops or a bowel movement does not occur after use, discontinue use and consult a health care provider. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Neuromuscular disease: Use with extreme caution in patients with myasthenia gravis or other neuromuscular disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with renal impairment; accumulation of magnesium may lead to magnesium intoxication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299631\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6221401\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9580&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alfacalcidol: May increase the serum concentration of Magnesium Salts.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha-Lipoic Acid: Magnesium Salts may decrease the absorption of Alpha-Lipoic Acid. Alpha-Lipoic Acid may decrease the absorption of Magnesium Salts. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aluminum Hydroxide: Citric Acid Derivatives may increase the absorption of Aluminum Hydroxide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bisphosphonate Derivatives: Magnesium Salts may decrease the serum concentration of Bisphosphonate Derivatives.  Management: Avoid administration of oral magnesium salts within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.<b> Exceptions: </b>Pamidronate; Zoledronic Acid.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcitriol (Systemic): May increase the serum concentration of Magnesium Salts. Management: Consider using a non-magnesium-containing antacid or phosphate-binding product in patients also receiving calcitriol. If magnesium-containing products must be used with calcitriol, serum magnesium concentrations should be monitored closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Channel Blockers: May enhance the adverse/toxic effect of Magnesium Salts. Magnesium Salts may enhance the hypotensive effect of Calcium Channel Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Polystyrene Sulfonate: Laxatives (Magnesium Containing) may enhance the adverse/toxic effect of Calcium Polystyrene Sulfonate. More specifically, concomitant use of calcium polystyrene sulfonate with magnesium-containing laxatives may result in metabolic alkalosis or with sorbitol may result in intestinal necrosis.  Management: Avoid concomitant use of calcium polystyrene sulfonate (rectal or oral) and magnesium-containing laxatives.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Magnesium Salts may decrease the serum concentration of Deferiprone.  Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dolutegravir: Magnesium Salts may decrease the serum concentration of Dolutegravir.  Management: Administer dolutegravir at least 2 hours before or 6 hours after oral magnesium salts. Administer the dolutegravir/rilpivirine combination product at least 4 hours before or 6 hours after oral magnesium salts.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxercalciferol: May enhance the hypermagnesemic effect of Magnesium Salts. Management: Consider using a non-magnesium-containing antacid or phosphate-binding product in patients also receiving doxercalciferol. If magnesium-containing products must be used with doxercalciferol, serum magnesium concentrations should be monitored closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eltrombopag: Magnesium Salts may decrease the serum concentration of Eltrombopag.  Management: Administer eltrombopag at least 2 hours before or 4 hours after oral administration of any magnesium-containing product.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gabapentin: Magnesium Salts may enhance the CNS depressant effect of Gabapentin. Specifically, high dose intravenous/epidural magnesium sulfate may enhance the CNS depressant effects of gabapentin. Magnesium Salts may decrease the serum concentration of Gabapentin.  Management: Administer gabapentin at least 2 hours after oral magnesium salts administration.  Monitor patients closely for evidence of reduced response to gabapentin therapy. Monitor for CNS depression if high dose IV/epidural magnesium sulfate is used.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levothyroxine: Magnesium Salts may decrease the serum concentration of Levothyroxine.  Management: Separate administration of oral levothyroxine and oral magnesium salts by at least 4 hours.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Fluoride (with ADE): Magnesium Salts may decrease the serum concentration of Multivitamins/Fluoride (with ADE). Specifically, magnesium salts may decrease fluoride absorption.  Management: To avoid this potential interaction separate the administration of magnesium salts from administration of a fluoride-containing product by at least 1 hour.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mycophenolate: Magnesium Salts may decrease the serum concentration of Mycophenolate.  Management: Separate doses of mycophenolate and oral magnesium salts. Monitor for reduced effects of mycophenolate if taken concomitant with oral magnesium salts.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular-Blocking Agents: Magnesium Salts may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphate Supplements: Magnesium Salts may decrease the serum concentration of Phosphate Supplements.  Management: Administer oral phosphate supplements as far apart from the administration of an oral magnesium salt as possible to minimize the significance of this interaction.<b> Exceptions: </b>Sodium Glycerophosphate Pentahydrate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinolones: Magnesium Salts may decrease the serum concentration of Quinolones.  Management: Administer oral quinolones several hours before (4 h for moxi/pe/spar-, 2 h for others) or after (8 h for moxi-, 6 h for cipro/dela-, 4 h for lome/pe-, 3 h for gemi-, and 2 h for levo-, nor-, or ofloxacin or nalidixic acid) oral magnesium salts.<b> Exceptions: </b>LevoFLOXacin (Oral Inhalation).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Raltegravir: Magnesium Salts may decrease the serum concentration of Raltegravir.  Management: Avoid the use of oral / enteral magnesium salts with raltegravir. No dose separation schedule has been established that adequately reduces the magnitude of interaction.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Polystyrene Sulfonate: Laxatives (Magnesium Containing) may enhance the adverse/toxic effect of Sodium Polystyrene Sulfonate. More specifically, concomitant use of sodium polystyrene sulfonate with magnesium-containing laxatives may result in metabolic alkalosis or with sorbitol may result in intestinal necrosis.  Management: Avoid concomitant use of sodium polystyrene sulfonate (rectal or oral) and magnesium-containing laxatives.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetracyclines: Magnesium Salts may decrease the absorption of Tetracyclines. Only applicable to oral preparations of each agent. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trientine: May decrease the serum concentration of Magnesium Salts. Magnesium Salts may decrease the serum concentration of Trientine.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14207678\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Magnesium crosses the placenta; serum concentrations in the fetus are similar to those in the mother (Idama, 1998; Osada, 2002). The American Gastroenterological Association considers the use of magnesium citrate as a laxative to be low risk in pregnancy, but long term use should be avoided (not the preferred treatment of chronic constipation) (Mahadevan, 2006).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14207679\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Magnesium is found in breast milk; concentrations remain constant during the first year of lactation and are not influenced by dietary intake under normal conditions (IOM, 1997).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9732700\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Some products may contain potassium and/or sodium.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F190813\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">Serum magnesium: 1.5-2.5 mg/dL; slightly different ranges are reported by different laboratories</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F190802\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Promotes bowel evacuation by causing osmotic retention of fluid which distends the colon with increased peristaltic activity</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F190818\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of laxative effect: Oral solution: 0.5 to 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: Up to 30%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (IOM 1997); feces (as unabsorbed drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323350\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Citrate of Magnesia Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.745 g/30 mL (296 mL): $1.65</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Citroma Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.745 g/30 mL (296 mL): $1.18</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F190822\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Argocytromag (PL);</li>\n      <li>Citramag (GB);</li>\n      <li>Epimag (AE, EG, JO, KW, QA, SA);</li>\n      <li>Magnesol (PL);</li>\n      <li>Usanimals (MX)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Chernow B, Smith J, Rainey TG, et al, &ldquo;Hypomagnesemia: Implications for the Critical Care Specialist,&rdquo; <i>Crit Care Med</i>, 1982, 10(3):193-6. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/magnesium-citrate-drug-information/abstract-text/7037303/pubmed\" target=\"_blank\" id=\"7037303\">7037303</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gams JG, &ldquo;Clinical Significance of Magnesium: A Review,&rdquo; <i>Drug Intell Clin Pharm</i>, 1987, 21(3):240-6. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/magnesium-citrate-drug-information/abstract-text/3552543/pubmed\" target=\"_blank\" id=\"3552543\">3552543</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Idama TO and Lindow SW, &quot;Magnesium Sulphate: A Review of Clinical Pharmacology Applied to Obstetrics,&quot;<i> Br J Obstet Gynaecol</i>, 1998, 105(3):260-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/magnesium-citrate-drug-information/abstract-text/9532984/pubmed\" target=\"_blank\" id=\"9532984\">9532984</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Institute of Medicine (IOM), <i>Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride</i>, Washington, DC: The National Academies Press, 1997.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mahadevan U and Kane S, &quot;American Gastroenterological Association Institute Medical Position Statement on the Use of Gastrointestinal Medications in Pregnancy,&quot; <i>Gastroenterology</i>, 2006, 131(1):278-82. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/magnesium-citrate-drug-information/abstract-text/16831610/pubmed\" target=\"_blank\" id=\"16831610\">16831610</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Osada H, Watanabe Y, Nishimura Y, et al, &quot;Profile of Trace Element Concentrations in the Feto-Placental Unit in Relation to Fetal Growth,&quot; <i>Acta Obstet Gynecol Scand</i>, 2002, 81(10):931-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/magnesium-citrate-drug-information/abstract-text/12366483/pubmed\" target=\"_blank\" id=\"12366483\">12366483</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vuignier BI, Oderda GM, Gorman RL, et al, &ldquo;Effects of Magnesium Citrate and Clidinium Bromide on the Excretion of Activated Charcoal in Normal Subjects,&rdquo; <i>DICP</i>, 1989, 23(1):26-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/magnesium-citrate-drug-information/abstract-text/2718479/pubmed\" target=\"_blank\" id=\"2718479\">2718479</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9580 Version 147.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F3884001\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F190827\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F190839\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F190828\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F190835\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F190829\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F190830\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F190812\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F190799\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F21963502\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F190816\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F190815\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25730798\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F190806\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F25855567\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F190803\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299631\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6221401\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F14207678\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F14207679\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F9732700\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F190813\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F190802\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F190818\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323350\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F190822\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9580|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=magnesium-citrate-patient-drug-information\" class=\"drug drug_patient\">Magnesium citrate: Patient drug information</a></li><li><a href=\"topic.htm?path=magnesium-citrate-pediatric-drug-information\" class=\"drug drug_pediatric\">Magnesium citrate: Pediatric drug information</a></li></ul></div></div>","javascript":null}